Fluorodeoxyglucose Metabolic Phenotypes Across Molecular Subgroups of Primary Colorectal Cancer: A Retrospective Three-Group Analysis

Background/Objectives: Increased FDG uptake has been reported in RAS-mutant colorectal cancer (CRC), whereas the FDG metabolic phenotype of BRAF-mutant CRC is less well characterized. We compared FDG PET-derived parameters among RAS-mutant, BRAF-mutant, and RAS/BRAF double-wild-type primary CRCs and explored associations between mucinous components and FDG uptake within each subgroup. Methods: This retrospective study included 105 patients with 106 treatment-naive primary CRCs (44 RAS-mutant, 11 BRAF-mutant, and 51 double-wild-type tumors). Maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Mucinous components were assessed from original histopathological reports in 86 evaluable tumors. Results: SUVmax, SUVpeak, SUVmean, and TLG differed among the three subgroups (p = 0.006, 0.015, 0.009, and 0.039, respectively), whereas MTV did not (p = 0.130). After Bonferroni correction, RAS-mutant tumors had higher SUVmax, SUVpeak, and SUVmean than double-wild-type tumors. No significant pairwise differences involving BRAF-mutant tumors were observed. Mucinous components were present in 11/34 RAS-mutant, 4/10 BRAF-mutant, and 4/42 double-wild-type tumors (p = 0.015). In exploratory within-subgroup analyses, BRAF-mutant tumors with mucinous components had lower SUVmax, SUVpeak, and SUVmean than those without mucinous components (exact p = 0.010 for each; Bonferroni-adjusted p = 0.048 for each); no corresponding differences were observed in the other subgroups. Conclusions: RAS-mutant primary CRC showed higher metabolic intensity than RAS/BRAF double-wild-type CRC, whereas BRAF-mutant tumors did not differ significantly from either subgroup. The association between mucinous components and lower metabolic intensity in BRAF-mutant CRC should be considered exploratory and hypothesis-generating.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-09-14
DOI
https://doi.org/10.3390/jcm15187113
Primary Topic
Colorectal Cancer Screening and Detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Fluorodeoxyglucose Metabolic Phenotypes Across Molecular Subgroups of Primary Colorectal Cancer: A Retrospective Three-Group Analysis

Mitsumasa Murao, Takashi Norikane, Katsuya Mitamura, Yoshihiro Nishiyama et al.
Journal of Clinical Medicine
Colorectal Cancer Screening and Detection
article

Fluorodeoxyglucose Metabolic Phenotypes Across Molecular Subgroups of Primary Colorectal Cancer: A Retrospective Three-Group Analysis

Mitsumasa Murao, Takashi Norikane, Katsuya Mitamura, Yoshihiro Nishiyama, Yuri Manabe, Yuka Yamamoto, Takafumi Obata, Riku Morita, Hiroyuki Okuyama
article en

Abstract

Background/Objectives: Increased FDG uptake has been reported in RAS-mutant colorectal cancer (CRC), whereas the FDG metabolic phenotype of BRAF-mutant CRC is less well characterized. We compared FDG PET-derived parameters among RAS-mutant, BRAF-mutant, and RAS/BRAF double-wild-type primary CRCs and explored associations between mucinous components and FDG uptake within each subgroup. Methods: This retrospective study included 105 patients with 106 treatment-naive primary CRCs (44 RAS-mutant, 11 BRAF-mutant, and 51 double-wild-type tumors). Maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Mucinous components were assessed from original histopathological reports in 86 evaluable tumors. Results: SUVmax, SUVpeak, SUVmean, and TLG differed among the three subgroups (p = 0.006, 0.015, 0.009, and 0.039, respectively), whereas MTV did not (p = 0.130). After Bonferroni correction, RAS-mutant tumors had higher SUVmax, SUVpeak, and SUVmean than double-wild-type tumors. No significant pairwise differences involving BRAF-mutant tumors were observed. Mucinous components were present in 11/34 RAS-mutant, 4/10 BRAF-mutant, and 4/42 double-wild-type tumors (p = 0.015). In exploratory within-subgroup analyses, BRAF-mutant tumors with mucinous components had lower SUVmax, SUVpeak, and SUVmean than those without mucinous components (exact p = 0.010 for each; Bonferroni-adjusted p = 0.048 for each); no corresponding differences were observed in the other subgroups. Conclusions: RAS-mutant primary CRC showed higher metabolic intensity than RAS/BRAF double-wild-type CRC, whereas BRAF-mutant tumors did not differ significantly from either subgroup. The association between mucinous components and lower metabolic intensity in BRAF-mutant CRC should be considered exploratory and hypothesis-generating.

Journal of Clinical MedicineVol. 15(18)
Kagawa University (JP)
Good health and well-being
Openalex Percentile: Top 13%
Colorectal Cancer Screening and Detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.